Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2024 Mar;26(3):69-80.
doi: 10.1007/s11926-023-01128-3. Epub 2023 Dec 22.

Pipeline Therapies for Gout

Kevin Yip  1 , Genna Braverman  2 , Linda Yue  2 , Theodore Fields  2
Affiliations
Review

Pipeline Therapies for Gout

Kevin Yip et al. Curr Rheumatol Rep. 2024 Mar.

Abstract

Purpose of review: Despite effective available treatments, gout management is often unsuccessful in getting patients to target serum urate goal and in managing flares in the setting of comorbidities. Studies addressing future treatment options for short- and long-term management are reviewed.

Recent findings: URAT-1 blocking agents have been helpful but have had limitations related to effects on renal function, lack of efficacy with renal impairment, and potential to increase renal stones. Dotinurad may function in the setting of decreased renal function. Arhalofenate has anti-URAT-1 activity and may also blunt gout flares. A new xanthine oxidase inhibitor (XOI), tigulixostat, is under study. New uricase treatments manufactured in combination with agents that can reduce immunogenicity may make uricase treatment simpler. A unique strategy of inhibiting gut uricase may offer the benefits of avoiding systemic absorption. For gout flares, IL-1β inhibitor studies in progress include different dosing schedules. Dapansutrile, an oral agent under investigation, inhibits activation of the NLRP3 inflammasome and may be an effective anti-inflammatory. New treatments for gout that are under study may work in the setting of comorbidities, simplify management, utilize new mechanisms, or have reduced side effects.

Keywords: Gout; Hyperuricemia; IL-1β inhibitors; URAT1; Uricosurics; Xanthine oxidase inhibitors.

PubMed Disclaimer

References

Papers of particular interest, published recently, have been highlighted as: • Of importance
    1. Li L, Yang C, Zhao Y, Zeng X, Liu F, Fu P. Is hyperuricemia an independent risk factor for new-onset chronic kidney disease?: A systematic review and meta-analysis based on observational cohort studies. BMC Nephrology. 2014;15:122. https://doi.org/10.1186/1471-2369-15-122 . - DOI - PubMed - PMC
    1. Cicero AF, Salvi P, D’Addato S, Rosticci M, Borghi C. Association between serum uric acid, hypertension, vascular stiffness and subclinical atherosclerosis: data from the Brisighella Heart Study. J Hyper. 2014;32(1):57–64. https://doi.org/10.1097/HJH.0b013e328365b916 . - DOI
    1. Choi HK, McCormick N, Yokose C. Excess comorbidities in gout: the causal paradigm and pleiotropic approaches to care. Nature Rev Rheuma. 2022;18(2):97–111. https://doi.org/10.1038/s41584-021-00725-9 . - DOI
    1. Lv Q, Meng XF, He FF, Chen S, Su H, Xiong J, et al. High serum uric acid and increased risk of type 2 diabetes: a systemic review and meta-analysis of prospective cohort studies. PloS One. 2013;8(2):e56864. https://doi.org/10.1371/journal.pone.0056864 . - DOI - PubMed - PMC
    1. Cipolletta E, Tata LJ, Nakafero G, Avery AJ, Mamas MA, Abhishek A. Risk of venous thromboembolism with gout flares. Arthritis & rheumatology (Hoboken, NJ). 2023. https://doi.org/10.1002/art.42480 .

LinkOut - more resources